Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Alan Menter

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of the American Academy of Dermatology|June 14, 2002
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Alastair Carruthers, Nicholas J Lowe, M Alan Menter, et al.
Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Immune-mediated conditionsJeffrey D Cizenski, Pablo Michel, Ian T Watson, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
Journal of the American Academy of Dermatology|May 8, 2003
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein, John Y M Koo, Gerald G Krueger, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 TrialsM Alan Menter, Kim A Papp, Jennifer Cather, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|December 3, 2016
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasisApril W Armstrong, Michael P Siegel, Jerry Bagel, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of the American Academy of Dermatology|June 14, 2002
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Alastair Carruthers, Nicholas J Lowe, M Alan Menter, et al.
Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Immune-mediated conditionsJeffrey D Cizenski, Pablo Michel, Ian T Watson, et al.
Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
Journal of the American Academy of Dermatology|May 8, 2003
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein, John Y M Koo, Gerald G Krueger, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 TrialsM Alan Menter, Kim A Papp, Jennifer Cather, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|December 3, 2016
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasisApril W Armstrong, Michael P Siegel, Jerry Bagel, et al.
Pageof 4